18
0 (0%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.13 | ||
| P/S | 3.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 21.42 | ||
| P/tB | N/A | ||
| EV/EBITDA | -13.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.88% | ||
| ROE | -380.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -60.24% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.11 | ||
| Quick Ratio | 4.46 | ||
| Altman-Z | 0.7 |
ChartMill assigns a fundamental rating of 4 / 10 to SCMP.
ChartMill assigns a valuation rating of 3 / 10 to Sucampo Pharmaceuticals (SCMP). This can be considered as Overvalued.
Sucampo Pharmaceuticals (SCMP) has a profitability rating of 4 / 10.
The financial health rating of Sucampo Pharmaceuticals (SCMP) is 4 / 10.
The Earnings per Share (EPS) of Sucampo Pharmaceuticals (SCMP) is expected to grow by 165.03% in the next year.